Document:

Exhibit

Exhibit 4.3

FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT
THIS FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of February 6, 2019, by and among Health Catalyst, Inc., a Delaware corporation (the “Company”), and the Persons listed on Schedule I attached hereto (each, an “Investor” and collectively, the “Investors”).
WHEREAS, certain of the parties to this Agreement are parties to a Series F Stock Purchase Agreement, dated as of the date hereof (the “Stock Purchase Agreement”), pursuant to which, among other things, certain of the Investors shall purchase shares of the Company’s newly-authorized Series F Preferred stock, par value $0.001 per share (the “Series F Preferred”);
WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred stock, par value $0.001 per share (the “Series A Preferred”), Series B Preferred stock, par value $0.001 per share (the “Series B Preferred”), Series C Preferred stock, par value $0.001 per share (the “Series C Preferred”), Series D Preferred stock, par value $0.01 per share (the “Series D Preferred”), and Series E Preferred stock, par value $0.01 per share (the “Series E Preferred” and together with the Series A Preferred, the Series B Preferred, and the Series C Preferred, Series D Preferred, and Series F Preferred, the “Preferred Stock”), and possess information rights, rights of first offer, and other rights pursuant to a Fourth Amended and Restated Investor Rights Agreement, dated as of February 9, 2016, by and among the Company and such investors (the “Old Investor Rights Agreement”);
WHEREAS, the Existing Investors desire to amend and restate the Old Investor Rights Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted under the Old Investor Rights Agreement; and WHEREAS, in order to induce the Investors to enter into the Stock Purchase Agreement and consummate the transactions contemplated thereby, the Company and the Existing Investors have agreed to amend and restate the Old Investor Rights Agreement in its entirety and enter into this Agreement for the benefit of the Investors.
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows:
Section 1.    Covenants.
1A.    Financial Statements and Other Information.  The Company shall deliver to each Investor upon the request of that Investor (so long as such Investor holds any shares of Preferred Stock or any Underlying Common Stock):
(i)    within thirty (30) days after the end of each monthly accounting period in each fiscal year, unaudited consolidated statements of income or operations, stockholders’ equity (or the equivalent) and cash flows of the Company and its subsidiaries on a combined basis for such monthly period and for the period from the beginning of the fiscal year to the end of such month, 

and an unaudited consolidated balance sheet of the Company and its subsidiaries on a combined basis as of the end of such monthly period, setting forth for each monthly accounting period in each fiscal year comparisons to the Company’s annual budget and to the corresponding period in the preceding fiscal year, and all such statements shall be prepared in accordance with GAAP, consistently applied;
(ii)    within one hundred twenty (120) days after the end of each fiscal year, consolidated statements of income or operations, stockholders’ equity (or the equivalent) and cash flows of the Company and its subsidiaries on a combined basis for such fiscal year, and a consolidated balance sheet of the Company and its subsidiaries on a combined basis as of the end of such fiscal year, setting forth in each case comparisons to the Company’s annual budget and to the preceding fiscal year, all prepared in accordance with GAAP, consistently applied and accompanied by (a) an unqualified opinion of the Company’s accounting firm (selected by the Board, but subject to the reasonable approval of the holders of a majority of the Preferred Stock if such firm is not a “Big Four” accounting firm) and (b) a copy of such firm’s annual management letter to the Company’s audit committee;
(iii)    promptly after receipt by the Company, statements of income or operations, stockholders’ equity (or the equivalent) and cash flows of each Person in which the Company has a Long-Term Investment;
(iv)    promptly after receipt by the Company, any other financial statements or material reports concerning each Person in which the Company has a Long-Term Investment;
(v)    promptly upon receipt thereof, any additional reports, management letters or other detailed information concerning significant aspects of the Company’s or any of its subsidiaries’ operations or financial affairs given to the Company by its independent accountants (and not otherwise contained in other materials provided hereunder);
(vi)    no later than 60 calendar days following the commencement of each fiscal year, an annual budget and operating plan prepared on a quarterly basis for the Company and its subsidiaries for such fiscal year (displaying anticipated statements of income and cash flows and balance sheets and approved by the Board), and promptly upon preparation thereof any other significant budgets or operating plans prepared by the Company and any revisions of such annual or other budgets or operating plans, and within thirty (30) days after any quarterly period in which there is a material adverse deviation from the annual budget, a certificate explaining the deviation and what actions the Company has taken and proposes to take with respect thereto;
(vii)    promptly after the discovery or receipt of notice of any noncompliance or default under any material agreement to which it or any of its subsidiaries is a party or any material adverse change, event or circumstance affecting the Company or any of its subsidiaries (including the filing of any material litigation against the Company or any of its subsidiaries or the existence of any known material dispute with any Person which involves a reasonable likelihood of such 

2

litigation being commenced), notice (written or unwritten) thereof which specifies the nature and period of existence thereof and what actions the Company and/or its subsidiaries have taken and propose to take with respect thereto; and (viii) with reasonable promptness, such other financial data and information (including regulatory/compliance information) concerning the Company and its subsidiaries as any such Investor may reasonably request; provided that the Company shall not be obligated to provide any documents or information to an Investor if (i) the Company reasonably determines in good faith that such documents or information is a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the Company’s counsel determines that such disclosure would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel.
Each of the financial statements referred to in subparagraphs (i) and (ii) above shall present fairly in all material respects the financial condition and operating results of the Company and its subsidiaries as and to the extent specified above as of the dates and for the periods set forth therein, subject in the case of the unaudited financial statements to changes resulting from normal year-end audit adjustments for recurring accruals (none of which would, alone or in the aggregate, be materially adverse to the financial condition, operating results, value, assets, operations or business prospects of the Company and its subsidiaries taken as a whole) of the types included in audited financials from prior fiscal years and the absence of footnotes with respect thereto.  Except as otherwise required by law or judicial order or decree or by any governmental agency or authority, each Person entitled to receive information regarding the Company and its subsidiaries under this Paragraph 1A or Paragraph 1B below shall use the same standards and controls which such Person uses to maintain the confidentiality of its own confidential information (but in no event less than reasonable care) to maintain the confidentiality of all nonpublic information of the Company and its subsidiaries obtained by it pursuant to this Paragraph 1A or Paragraph 1B below; provided that each such Person may disclose such information in connection with any proposed sale or transfer of any Preferred Stock or Underlying Common Stock if such Person’s transferee agrees in writing to be bound by the provisions hereof.  For purposes of this Agreement, all holdings of Preferred Stock or Underlying Common Stock by Persons who are affiliates of each other shall be aggregated for purposes of meeting any threshold tests under this Agreement and the Registration Agreement.  Notwithstanding anything to the contrary herein, Kaiser Permanente Ventures, LLC - Series A, Kaiser Permanente Ventures, LLC - Series B and The Permanent Federation LLC - Series J shall be deemed to be affiliates of each other.
1B.    Certain Inspection Rights.  The Company shall permit any representatives designated by any Investor (so long as such Investor holds any Preferred Stock or Underlying Common Stock) at such Investor’s expense, and upon reasonable notice and during normal business hours, to (i) visit and inspect any of the properties of the Company and its subsidiaries, (ii) examine the corporate, financial and other records of the Company and its subsidiaries and make copies thereof or extracts therefrom and (iii) consult with the directors, managers, officers, compliance personnel, key employees and independent accountants of the Company and its subsidiaries concerning the affairs, compliance or regulatory status, finances and accounts of the Company and 

3

its subsidiaries; provided that the Company shall not be obligated to permit the rights granted under this Paragraph 1B to an Investor if Company counsel determines in a written opinion that such rights would waive the attorney-client privilege in any pending litigation.  Subject to the foregoing limitations, the presentation of an executed copy of this Agreement by any Investor or such other holder to the Company’s independent accountants shall constitute the Company’s permission to its independent accountants to participate in discussions with such Investors or their respective officers, directors, managers, employees, agents or advisors.
1C.    Observer Rights.
(i)    As long as one or more investment vehicles managed by Sands Capital Ventures, LLC or its affiliate (together, “Sands”) collectively own not less than 750,000 shares of the Company’s capital stock (as adjusted for subsequent stock splits, combinations, stock dividends or other similar events) the Company shall invite a representative of Sands to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company.
(ii)    As long as Tenaya Capital VI, LP (“Tenaya”) owns not less than 750,000 shares of the Company’s capital stock (as adjusted for subsequent stock splits, combinations, stock dividends or other similar events) the Company shall invite a representative of Tenaya to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company.
(iii)    As long as OrbiMed Royalty Opportunities II, LP together with its affiliates (“OrbiMed”) owns not less than 150,000 shares of the Company’s capital stock (as adjusted for subsequent stock splits, combinations, stock dividends or other similar events) the Company shall invite a representative of OrbiMed to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, 

4

consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company.
1D.    Reserved.
1E.    Certain Negative Covenants in Favor of Preferred Stock.
(i)    Majority Vote Covenants.  So long as at least 5,000,000 shares of Preferred Stock (subject to proportionate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) remain outstanding, the Company shall not, unless it has received the prior written consent of the holders of a majority of the outstanding shares of Series A Preferred stock:
(a)    amend, supplement, modify, alter, repeal, terminate or waive any provision of the Company’s Certificate of Incorporation, bylaws or any other organizational, charter or constituent agreement or document, or file any resolution of the Board with the Delaware Secretary of State;
(b)    directly or indirectly (i) redeem, repurchase or otherwise acquire, or permit any of its subsidiaries to redeem, purchase or otherwise acquire, any of the Company’s or any subsidiary’s capital stock or other ownership interests or other equity securities (including warrants, options and other rights to acquire such capital stock or other ownership interests or other equity securities), other than (A) redemptions expressly authorized in the Certificate of Incorporation, or (B) repurchase or cancellation of vested stock options pursuant to the Company’s equity incentive plan for an aggregate purchase price of no more than $500,000 in any twelve (12)-month period so long as no event of noncompliance or default under any material agreement to which the Company or any of its subsidiaries is a party is in existence immediately prior to or is otherwise caused by any such repurchase; or (ii) redeem, repurchase or make any payments with respect to any stock or stock appreciation rights, phantom stock or similar rights or plans, or permit any of its subsidiaries to so redeem, repurchase or make such payments;
(c)    directly or indirectly declare or pay, or permit any of its subsidiaries to declare or pay, any dividends or make any distributions upon any of its capital stock or other ownership interests or other equity securities, except that any subsidiary of the Company may pay dividends or make distributions to the Company or any wholly owned subsidiary of the Company;

5

(d)    create, incur, assume or suffer to exist, or permit any subsidiary to create, incur, assume or suffer to exist, any Indebtedness or amend, modify, supplement or waive any provision of the agreements evidencing any existing Indebtedness of the Company or any subsidiary, except for Indebtedness in any individual circumstance not to exceed $1,000,000 or in an aggregate amount outstanding at any given time not to exceed $5,000,000; or
(e)    engage in a Fundamental Change or a Change in Ownership (each as defined in the Company’s Certificate of Incorporation);
(f)    sell, lease or otherwise dispose of, or permit any subsidiary to sell, license or otherwise dispose of any material assets (including the capital stock or other ownership interest of any of its subsidiaries) outside the ordinary course of business or sell, lease, license, sub-license or permanently dispose of any of the Company’s or any subsidiary’s material Intellectual Property Rights outside the ordinary course of business;
(g)    acquire, or permit any subsidiary to acquire, any interest in any company or business (whether by a purchase of assets, purchase of stock or other equity interests, merger or otherwise) or enter into or permit any Subsidiary to enter into any joint venture, except to the extent such acquisitions or investments do not exceed $2,000,000 per year, in the aggregate;
(h)    enter into, amend, modify or supplement any agreement, transaction, commitment or arrangement with any of its or any of its Subsidiaries’ or any of its affiliates’ direct or indirect officers, directors, key employees, stockholders or affiliates or with any Person related by blood, marriage or adoption to any such Person or any entity in which any of the foregoing owns a beneficial interest, except for customary employment arrangements or employment agreements, benefit programs and other arrangements as approved by the Board or the Compensation Committee (which approval must include the affirmative vote or consent of an Investor Director) and subject to subparagraph (i) below; or
(i)    except as expressly contemplated by the Stock Purchase Agreement, amend or modify any equity incentive plan, employee equity ownership plan, profit sharing plan, phantom equity plan, equity appreciation rights plan or any similar plan, program or arrangement of the Company or any of its subsidiaries as in existence as of the date hereof (including increasing the number of shares of capital stock available for issuance thereunder or allocating additional aggregate profits interests or profits participation rights to any such plan, program or arrangement) or (ii) adopt or permit any of its subsidiaries to adopt, any new plan, program or arrangement of any such type, or (c) issue, or permit any of its subsidiaries to issue (other than pursuant to such a plan, program or arrangement existing on the date hereof and expressly disclosed on the Schedules to the Stock Purchase Agreement or thereafter adopted in accordance with the terms of the Transaction Agreements) any equity securities (including Common Stock, rights to acquire Common Stock or other equity 

6

securities, capital stock, ownership interests, debt convertible into any of the foregoing or rights to acquire any of the foregoing) to its or its subsidiaries’ or affiliates’ officers, directors, employees, consultants or service providers.
(ii)    Supermajority Vote Covenants.  So long as 5,000,000 shares of Preferred Stock (subject to proportionate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) remain outstanding, the Company shall not, unless it has received the prior written consent of the holders of at least sixty-six percent (66%) of the outstanding shares of Preferred Stock:
(a)    liquidate, dissolve or wind up the Company or any of its subsidiaries or effect a recapitalization or reorganization in any form of transaction (including the formation of a parent holding company for the Company or a transaction to change the domicile of the Company);
(b)    authorize, issue or enter into any agreement providing for the issuance (contingent or otherwise) of any capital stock or other equity securities (or any securities convertible into or exchangeable or exercisable for any capital stock or other equity securities) having rights, preferences or privileges which are senior to or on a parity with the Preferred Stock with respect to the payment of dividends, redemptions, distributions upon liquidation or otherwise or permit any Subsidiary to issue any such securities to any Person other than the Company or a wholly owned Subsidiary, except as required in connection with any mandatory redemption of Preferred Stock pursuant to the Company’s Certificate of Incorporation;
(c)    engage in a Fundamental Change or a Change in Ownership (each as defined in the Company’s Certificate of Incorporation), except where the holders of Preferred Stock receive consideration per share of at least 1.0 times the Liquidation Value (as defined in the Company’s Certificate of Incorporation) of the Series F Preferred;
(d)    consummate an initial public offering of the Company’s equity securities (an “IPO”) or permit any of its subsidiaries or any of their respective corporate successors to consummate any such IPO; or
(e)    materially change, or cause or allow any of the Company’s subsidiaries to materially change, the business activities of the Company or any of its subsidiaries as currently conducted, or enter into, or permit any Subsidiary to enter into, the ownership, active management or operation of any business that is not related to the current business activities of the Company or any of its subsidiaries.
1F.    Termination of Covenants.  The covenants set forth in Paragraph 1A, Paragraph 1B, Paragraph 1C, Paragraph 1D and Paragraph 1E shall terminate and be of no further force or effect (i) upon consummation of the Company’s IPO under the Securities Act of 1933, as 

7

amended, and the rules and regulations promulgated thereunder, that is approved by the holders of outstanding Preferred Stock pursuant to subparagraph (ii)(d) of Paragraph 1E above, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act, (iii) upon a Change in Ownership or a Fundamental Change (each as defined in the Company’s Certificate of Incorporation) that is either approved by the holders of outstanding Preferred Stock pursuant to subparagraph (ii)(c) of Paragraph 1E above or does not require such approval, or (iv) upon a liquidation, dissolution or winding up of the Company that is approved by the holders of outstanding Preferred Stock pursuant to subparagraph (ii)(a) of Paragraph 1E above, whichever event occurs first.
Section 2.    Definitions.  For the purposes of this Agreement, the following terms have the meanings set forth below:
“Compensation Committee” means the Compensation Committee established by the Board, if any.
“GAAP” means United States generally accepted accounting principles.
“Indebtedness” means at a particular time, without duplication:  (i) all obligations of such Person for borrowed money or in respect of loans or advances, (ii) obligations of such Person evidenced by bonds, debentures, notes or other similar instruments or debt securities, (iii) commitments by which a Person assures a creditor against loss (including contingent reimbursement obligations with respect to letters of credit and bankers’ acceptances), (iv) obligations arising from cash/book overdrafts, (v) all obligations of such Person secured by a Lien, (vi) all guarantees of such Person in connection with any of the foregoing and any other indebtedness guaranteed in any manner by a Person (including guarantees in the form of an agreement to repurchase or reimburse), and (vii) all capital lease obligations.
“Intellectual Property Rights” means any and all intellectual and proprietary rights and rights in Confidential Information of every kind and description anywhere in the world, and all corresponding rights presently or hereafter existing, whether arising by operation of law, contract, license or otherwise, including all (i) patents and industrial designs (including utility model rights, design rights and industrial property rights), patent and industrial design applications, patent disclosures and inventions, together with all reissues, continuations, continuations-in-part, revisions, divisionals, extensions, and reexaminations in connection therewith, (ii) trademarks, service marks, trade dress, trade names, logos and corporate names and registrations and applications for registration thereof together with all of the goodwill associated therewith, (iii) Internet domain names and URLs and websites, (iv) copyrights (registered or unregistered) and copyright registrations and applications for registration thereof, (v) mask works and registrations and applications for registration thereof, (vi) copyrights, trade secret rights and other intellectual property rights in or to Software, records, technical drawings, programmer comments and annotations, data, databases and documentation thereof, and (vii) trade secret rights in and to Confidential Information (including ideas, formulas, compositions, inventions (whether patentable or unpatentable and 

8

whether or not reduced to practice), know-how, manufacturing and production processes and techniques, research and development information, drawings, architectures, layouts, product specifications, designs, plans, proposals, technical data, financial and marketing plans and customer and supplier lists and information).
“Investment” as applied to any Person means (i) any direct or indirect purchase or other acquisition by such Person of any notes, obligations, instruments, stock, securities or ownership interest (including partnership interest and joint venture interests) of any other Person and (ii) any capital contribution by such to any other Person.
“Investor Director” shall have the meaning given to such term in the Stockholders Agreement.
“Lien” means any mortgage, pledge, security interest, encumbrance, lien or charge of any kind (including any conditional sale or other title retention agreement or lease in the nature thereof), any sale of receivables with recourse against the Company, any filing or agreement to file a financing statement as debtor under the Uniform Commercial Code or any similar statute.
“Long-Term Investment” means any Investment other than an Investment made in the ordinary course of business of the Company or any of its Subsidiaries.
“Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.
“Registration Agreement” means that certain Fifth Amended and Restated Registration Agreement, dated as of the date hereof, among the Company and the Investors.
“Securities Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar federal law then in force.
“Stockholders Agreement” means that certain Fifth Amended and Restated Stockholders Agreement, dated as of the date hereof, among the Company and certain of its stockholders.
“Transaction Agreements” means the Stock Purchase Agreement and all of the agreements entered into in connection therewith.
“Underlying Common Stock” means (i) the Common Stock issued or issuable upon conversion of the Preferred Stock and (ii) any Common Stock or other securities issued or issuable with respect to the securities referred to in clause (i) above by way of stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization.  For purposes of this Agreement, any Person who holds Preferred Stock shall be deemed to be the holder of the Underlying Common Stock obtainable upon conversion of the 

9

Preferred Stock in connection with the transfer thereof or otherwise regardless of any restriction or limitation on the conversion of the Preferred Stock, such Underlying Common Stock shall be deemed to be in existence, and such Person shall be entitled to exercise the rights of a holder of Underlying Common Stock hereunder.  As to any particular shares of Underlying Common Stock, such shares shall cease to be Underlying Common Stock when they have been (a) effectively registered under the Securities Act and disposed of in accordance with the registration statement covering them, (b) distributed to the public through a broker, dealer or market maker pursuant to Rule 144 under the Securities Act (or any similar provision then in force) or (c) repurchased by the Company or any Subsidiary.
Each capitalized term used but not defined herein shall have the meaning given to such term in the Stockholders Agreement.
Section 3.    Miscellaneous.
3A.    Right to Conduct Activities.  The Company acknowledges that the Investors and their affiliates, members, equity holders, director representatives, partners, employees, agents and other related persons (“Investor Parties”) are engaged in the business of investing in private and public companies in a wide range of industries, including the industry segment in which the Company operates (the “Company Industry Segment”).  Accordingly, the Company and the Investors acknowledge and agree that a Covered Person shall:
(i)    have no duty to the Company to refrain from participating as a director, investor or otherwise with respect to any company or other person or entity, including any such company or other person or entity that is engaged in the Company Industry Segment or is otherwise competitive with the Company, and (ii) in connection with making investment decisions, to the fullest extent permitted by law, have no obligation of confidentiality or other duty to the Company to refrain from using any information, including, but not limited to, market trend and market data, which comes into such Covered Person’s possession, whether as a director, investor or otherwise (the “Information Waiver”), provided that the Information Waiver shall not apply, and therefore such Covered Person shall be subject to such obligations and duties as would otherwise apply to such Covered Person under applicable law, if the information at issue (i) constitutes material non-public information concerning the Company, or (ii) is covered by a contractual obligation of confidentiality to which the Company is subject.
Notwithstanding anything in this Paragraph 3A to the contrary, nothing herein shall be construed as a waiver of any Covered Person’s duty of loyalty or obligation of confidentiality with respect to the disclosure of confidential information of the Company.  For the purposes of this Paragraph 3A, “Covered Persons” shall have the meaning set forth in the Company’s Stockholders Agreement.
3B.    Green Dot.  Neither the Company nor any of its Subsidiaries shall enter into any banking or nonbanking transaction or agreement with Green Dot Corporation or any of its Subsidiaries (including Next Estate Communications and Bonneville Bancorp) without the prior 

10

written consent of Sequoia Capital U.S. Growth Fund IV, L.P. and Sequoia Capital U.S. Growth Fund V, L.P.
3C.    Foreign Corrupt Practices Act Enforcement Actions.  The Company shall promptly notify each of the Investors should Company become aware of any Enforcement Action (as defined in the Stock Purchase Agreement).
3D.    Notice of Certain Events.  In the event the Company takes any action at any meeting at which an Investor Director is not present in regards to any of the following:
(i)    The Company shall give written notice to all holders of Preferred Stock at least 20 days prior to the date on which the Company closes its books or takes a record (a) with respect to any dividend or distribution upon Common Stock, (b) with respect to any pro rata subscription offer to holders of Common Stock or (c) for determining rights to vote with respect to any Organic Change (as such term is defined in the Company’s Certificate of Incorporation), dissolution or liquidation.
(ii)    The Company shall also give written notice to the holders of Preferred Stock at least 20 days prior to the date on which any Organic Change shall take place.
(iii)    If a Change in Ownership (as such term is defined in the Company’s Certificate of Incorporation) or a Fundamental Change (as such term is defined in the Company’s Certificate of Incorporation) is proposed to occur, the Company shall give written notice of such Change in Ownership or Fundamental Change describing in reasonable detail the material terms and date of consummation thereof to each holder of Preferred Stock not more than 45 days nor less than 20 days prior to the consummation of such Change in Ownership or Fundamental Change, and the Company shall give each holder of Preferred Stock prompt written notice of any material change in the terms or timing of such transaction.
3E.    Remedies.  Each holder of Preferred Stock and Underlying Common Stock shall have all rights and remedies set forth in this Agreement, the Seventh Amended and Restated Certificate of Incorporation (as amended from time to time) and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under applicable law.  Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law.  The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that, in addition to any other rights and remedies existing in its favor, any party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction (without posting any bond or other security) in order to enforce or prevent violation of the provisions of this Agreement.

11

3F.    Consent to Amendments.  Except as otherwise expressly provided herein, the provisions of this Agreement may be amended and the Company may take any action herein prohibited, or fail to perform any act herein required to be performed by it, only if the Company has obtained the prior written consent of the holders of a majority of the Preferred Stock, provided, however, that the holders of a majority of the Preferred Stock may waive compliance in writing with any provision hereof intended for the benefit of the holders of the Preferred Stock at any time.  No other course of dealing between the Company and a holder of Preferred Stock or any delay in exercising any rights hereunder shall operate as a waiver of any rights of any such Persons.  Notwithstanding the foregoing, (i) no provision of Section 1E(ii) shall be amended, modified or waived without the prior written consent of the holders of at least sixty-six percent (66%) of the Preferred Stock, (ii) Section 1C(i) may be amended only with the written consent of Sands, (iii) Section 1C(ii) may be amended only with the written consent of Tenaya, (iv) Section 1C(iii) may be amended only with the written consent of OrbiMed, and (v) if an amendment would treat an Investor in a materially disproportionate and adverse manner relative to the other Investors, then the amendment shall also require the consent of such Investor so adversely treated.
3G.    Successors and Assigns.  Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not, and whether or not any express assignment has been made, the provisions of this Agreement which are for any Investor’s benefit as an Investor or holder of Preferred Stock or Underlying Common Stock are also for the benefit of, and enforceable by, any subsequent holder of such Preferred Stock or Underlying Common Stock.
3H.    Capital and Surplus; Special Reserves.  The Company agrees that the capital of the Company with respect to the Preferred Stock issued pursuant to the Stock Purchase Agreement shall be equal to the aggregate par value of such shares and that it shall not increase the capital of the Company with respect to any shares of the Company’s capital stock at any time on or after the date of this Agreement without the prior consent of the holders of a majority of the Preferred Stock.  The Company also agrees that it shall not create any special reserves under any applicable law without the prior written consent of the holders of a majority of the Preferred Stock.
3I.    Generally Accepted Accounting Principles.  Where any accounting determination or calculation is required to be made under this Agreement, such determination or calculation (unless otherwise provided) shall be made in accordance with GAAP, consistently applied, except that if because of a change in generally accepted accounting principles the Company would have to alter a previously utilized accounting method or policy in order to remain in compliance with GAAP, such determination or calculation shall continue to be made in accordance with the Company’s previous accounting methods and policies, unless otherwise directed by the holders of a majority of the Preferred Stock.

12

3J.    Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.
3K.    Counterparts.  This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same Agreement.
3L.    Descriptive Headings; Interpretation.  The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement.  The use of the word “including” in this Agreement shall mean “including without limitation”.
3M.    Governing Law.  All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.
3N.    Notices.  All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (i) when delivered personally to the recipient, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; provided that such notice under this clause (ii) shall not be effective unless within one business day of the notice a copy of such notice is dispatched to the recipient by first class mail, return receipt requested, or reputable overnight courier service (charges prepaid), (iii) one business day after it is sent to the recipient by reputable overnight courier service (charges prepaid) or (iv) five days after it is mailed to the recipient by first class mail, return receipt requested.  Such notices, demands and other communications shall be sent to the Company at the address specified below, to each Investor at the address indicated on Schedule I attached hereto, or at such address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party.  Any party may change its address for receipt of notice by providing sending prior written notice of the change to the sending party.

13

The Company:
Health Catalyst, Inc. 
3165 East Millrock Drive, Suite 450 
Salt Lake City, UT 84121 
Attention:    Dan Orenstein 
Telephone:    801-708-6800 
Fax:    801-365-0076
3O.    No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.  The parties hereto intend that each covenant and agreement contained herein shall have independent significance.  If any party has breached any covenant or agreement contained herein in any respect, the fact that there exists another covenant or agreement relating to the same subject matter (regardless of the relative levels of specificity) which such party has not breached shall not detract from or mitigate the fact that such party is in breach of the first covenant or agreement.
3P.    Third-Party Beneficiaries.  The parties hereto acknowledge and agree that all rights and privileges (including approvals and consents and rights to provide or withhold approval or consent) that may be exercised hereunder by the Investors or some group of Investors or the holders of some requisite percentage or amount of the Preferred Stock or Underlying Common Stock may be exercised by and for the benefit of the Investor Parties and for their own accounts to the same extent as if such Investor Parties were parties hereto (unless otherwise agreed by each such Investor Parties).  Notwithstanding anything to the contrary in this Agreement, this Paragraph 3Q may not be amended or modified without the prior written consent of the Investor Parties.
3Q.    Amendment of Old Investors Rights Agreement; Complete Agreement.  The Old Investors Rights Agreement is hereby amended and restated in its entirety by this Agreement and the provisions of the Old Investors Rights Agreement shall no longer be of any force or effect.  This Agreement and the other agreements and instruments referred to herein contain the complete agreement between the parties hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations by or between the parties hereto (whether written or oral) which may have related to the subject matter hereof or thereof in any way.

14

3R.    Additional Investors.  Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder.  No action or consent by the Investors shall be required for such joinder to this Agreement by such additional investor, so long as such additional investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.
*     *     *     *     *

15

IN WITNESS WHEREOF, the parties hereto have executed this Investor Rights Agreement on the date first written above.
	
		
	HEALTH CATALYST, INC

	 
	 

	By:
	/s/ Daniel D. Burton

	Name:
	Daniel D. Burton

	Title:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS:

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND IV, L.P.

	SEQUOIA CAPITAL USGF PRINCIPALS FUND IV, L.P.

	 
	 

	By:
	SCGF IV Management, L.P., a Cayman Islands exempted limited partnership, General Partner of Each

	 
	 

	By:
	SC US (TTGP), LTD., a Cayman Islands limited liability company

	 
	 

	Its:
	General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Managing Director

	 
	 

	SC US GF V HOLDINGS, LTD.

	a Cayman Islands exempted company

	 
	 

	By:  Sequoia Capital U.S. Growth Fund V, L.P. and Sequoia Capital USGF Principals Fund V, L.P., both Cayman Islands Exempted Limited Partnerships, its Members

	 
	 

	By:  SCGF V Management, L.P.,

	a Cayman Islands Exempted Limited Partnership, its General Partner

	 
	 

	By:  SC US (TTGP), LTD.,

	a Cayman Islands Exempted company, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND V, L.P.

	a Cayman Islands exempted limited partnership

	 
	 

	By:
	SCGF V MANAGEMENT, L.P.,

	a Cayman Islands exempted limited partnership, its General Partner

	 
	 

	By:
	SC US (TTGP), LTD.,

	a Cayman Islands exempted company, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	NORWEST VENTURE PARTNERS XI, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

	 
	 

	NORWEST VENTURE PARTNERS XII, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	HQC ACQUISITION, LLC

	 
	 

	By:
	/s/ Fraser Bullock

	Name:
	Fraser Bullock

	Title:
	President

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES A

	 
	 

	By:
	/s/ Thomas Meier

	Name:
	Thomas Meier

	Title:
	SVP & Treasurer

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES B

	 
	 

	By:
	/s/ Chris Grant

	Name:
	Chris Grant

	Title:
	Member, Managing Committee

	 
	 

	THE PERMANENTE FEDERATION LLC - SERIES J

	 
	 

	By:
	/s/ Anne Cadwell

	Name:
	Anne Cadwell

	Title:
	CFO

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	CHV FUND II, LLC

	 
	 

	By:
	CHV Fund II Management, LLC

	Its:
	Manager

	 
	 

	By:
	/s/ John D. Huesing

	Name:
	John D. Huesing

	Its:
	Authorized Representative

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P.

	Its:
	General Partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC2, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC3, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC4, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P., its general partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC, its general partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	TENAYA CAPITAL VI, LP

	 
	 

	By:
	Tenaya Capital VI GP, LLC, its General Partner

	 
	 

	By:
	/s/ Dorian Merritt

	Name:
	Dorian Merritt

	Its:
	Attorney-In-Fact

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ZIONS SBIC LLC

	 
	 

	By:
	/s/ Kent Madsen

	Name:
	Kent Madsen

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	BRIGHAM YOUNG UNIVERSITY,

	a Utah nonprofit corporation

	 
	 

	By:
	/s/ G P Williams

	Name:
	G P Williams

	Title:
	Faculty Advisor

Cougar Capital contact information:
Brigham Young University, 
a Utah nonprofit corporation 
c/o Cougar Capital Program 
David Paul – Treasurer 
A-153 ASB 
Provo. UT 84602 
Email:  davidwpaul@byu.edu 
Phone:  801-422-4887

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UNIVERSITY GROWTH FUND I, L.P.

	 
	 

	By:
	UGFIGP,LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Tom Stringham

	Name:
	Tom Stringham

	Its:
	Manager

	 
	 

	By:
	/s/ Peter Harris

	Name:
	Peter Harris

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UPMC

	 
	 

	By:
	/s/ C. Talbot Heppenstall, Jr.

	Name:
	C. Talbot Heppenstall, Jr.

	Its:
	Treasurer

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	OSF HEALTHCARE SYSTEM,

	an Illinois not for profit corporation

	 
	 

	By:
	/s/ Robert C. Sehring

	Name:
	Robert C. Sehring

	Its:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ John A. Kane

	John A. Kane

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	JOHN MUIR HEALTH

	 
	 

	By:
	/s/ Chris Pass

	Name:
	Chris Pass

	Its:
	Chief Financial Officer

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	IOWA HEALTH SYSTEM D/B/A UNITYPOINT HEALTH

	 
	 

	By:
	/s/ Matthew Kirschner

	Name:
	Matthew Kirschner

	Title:
	Vice President, Treasury

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ORBIMED ROYALTY OPPORTUNITIES II, LP

	 
	 

	By OrbiMed Advisors LLC,

	its investment manager

	 
	 

	By:
	/s/ W. Carter Neild

	Name:
	W. Carter Neild

	Its:
	Member

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ Brent C. James

	Brent C. James

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ W. David Hemingway

	W. David Hemingway

[Signature Page to Fifth Amended and Restated Investor Rights Agreement]

SCHEDULE I
SCHEDULE OF INVESTORS
	
			
	Investor:
	Notice Address:
	With a copy to (which shall not constitute notice to such Investor):

	Sequoia Capital 
U.S. Growth 
Fund V, L.P.
	c/o Sequoia Capital 
2800 Sand Hill Road, Suite 101 
Menlo Park, CA 94025 
Telephone:  (650) 854-3927 
Telecopy:  (650) 854-2977 
Attention:  Michael Dixon
	Kirkland & Ellis LLP 
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	SC US GF V Holdings, LTD.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital USGF Principals Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital U.S. Growth
Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture Partners XI, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture
Partners XII, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

Schedule of Investors for Series F Investor Rights Agreement

	
			
	HQC Acquisition,
LLC
	c/o Sorenson Capital 
3400 Ashton Blvd., Suite 400 
Lehi, UT 84043 
Telephone:  (801) 407-8444 
Telecopy:  (801) 407-8410 
Attention:  Fraser Bullock
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Matoaka, LLC
	c/o Sequoia Capital 
2800 Sand Hill Road, Suite 101 
Menlo Park, CA 94025 
Telephone:  (650) 854-3927 
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP 
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050 
Telecopy:  (650) 859-7500 
Attention:  Adam D. Phillips

	Todd Cozzens
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP
3330 Hillview Avenue Palo Alto, CA 94304 Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Kaiser Permanente Ventures, LLC -Series A
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	Kaiser Permanente Ventures, LLC -Series B
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	The Permanente Federation LLC -Series J
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	CHV Fund II, LLC
	340 W. 10th Street, Suite 2100 Indianapolis, IN 46202 Attention:  John D. Huesing Telephone:  (317) 963-1310
	 

	Partners HealthCare System, Inc.
	101 Huntington Avenue, 4th Floor
Boston, MA 02199
Attn:  Roger Kitterman
Telephone:  (617) 954-9500
Fax:  (917) 954-9356
	 

	Sands Capital Private Growth
Fund, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

Schedule of Investors for Series F Investor Rights Agreement

	
			
	Sands Capital Private Growth
Fund-HC, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth
Fund-HC2, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth
Fund-HC3, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC4, L.P
	Jonathan P. Goodman, General Counsel 1000 Wilson Blvd., Suite 3000 Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Allina Health System
	2925 Chicago Avenue 
Minneapolis, MN 55407 
Telephone:  (612) 262-5403 
Facsimile:  (612) 262-4264 
Attention:  General Counsel
	Faegre Baker Daniels LLP 
2200 Wells Fargo Center 
90 South Seventh Street 
Minneapolis, MN 55402-3901 
Telephone:  (612) 766-7790 
Telecopy:  (612) 554-6467
Attention:  Mark D. Pihlstrom

	Tenaya Capital
VI, LP
	c/o Tenaya Capital, LLC
3280 Alpine Road
Portola Valley, CA 94028
Phone:  650-687-6500
Attn:  Stewart Gollmer and Dave Markland
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Zions SBIC LLC
	15 West South Temple #500 
Salt Lake City, UT 84111 
Attn:  Kent Madsen
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Leavitt Equity Partners I, L.P.
	299 S. Main Street, Suite 2300 
Salt Lake City, UT 84111 
Attn:  Taylor Leavitt
	 

Schedule of Investors for Series F Investor Rights Agreement

	
			
	Brigham Young University (Cougar Capital)
	Brigham Young University, 
a Utah nonprofit corporation 
c/o Cougar Capital Program 
David Paul – Treasurer 
A-153 ASB
Provo, UT 84602
Email:  davidwpaul@byu.edu 
Phone:  801-422-4887
	 

	University Growth Fund I, L.P.
	University Growth Fund 
299 South Main, Suite 357 
Salt Lake City, UT 84111 
Attn:  Tom Stringham
	 

	UPMC
	UPMC
U.S. Steel Tower, Suite 6071
600 Grant Street
Pittsburgh, PA 15219
Attn:  Senior Associate Counsel and
Vice President
	 

	OSF Healthcare System
	Attn:  Robert C. Sehring, CEO 
800 NE Glen Oak Avenue 
Peoria, IL 61603. 
Fax:  309-655-6869
	 

	Leerink Capital Investors I L.P.
	One Federal Street 
Boston, MA 02110 
 Attn:  Todd Cozzens
	 

	Leerink Transformation Fund I L.P.
	One Federal Street, 25th Floor
Boston, MA 02110
Attn:  Todd Cozzens 
Phone:  (617) 918-4821
Fax:  (617) 918-4921
todd@LTPequity.com
	 

	MultiCare Health System
	MultiCare Health System 
737 S. Fawcett Ave. 
MS:  737-4-CFO 
Tacoma, WA 98402 
Attn:  Judy Swain 
Phone:  253.459.8003 
Fax:  253.459.7854
Judy.swain@multicare.org
	 

	John A. Kane
	18242 Via Caprini Drive 
Ft Myers, FL 33913 
Fax:  239-689-8187
Cell:  802-999-6769
Email jackakane@gmail.com
	 

Schedule of Investors for Series F Investor Rights Agreement

	
			
	John Muir Health
	1450 Treat Blvd Suite #350 
Walnut Creek, CA 94597 
Attn:  Ravi Hundal M.D. or 
Taejoon Ahn M.D. MPH CPE 
Taejoon.Ahn_MD@johnmuirhealth.com
	1400 Treat Boulevard 
Walnut Creek, CA 94597 
Attn:  General Counsel 
Phone:  925-941-2217
Fax:  925-952-2979
max.reynolds@johnmuirhealth.com

	John Muir Medical Group, Inc.
	1400 Treat Boulevard 
Walnut Creek, CA 94597 
Attn:  Chris Pass, CFO 
Phone:  (925) 941-2622
Fax:  (925) 952-2979
chris.pass@johnmuirhealth.com
	 

	Omkara LLC
	Omkara LLC 
c/o Anita Pramoda 
6085 West Twain Ave., Suite 101 
Las Vegas, NV 89103
	 

	Ben Fatto Limited Partnership
	Ben Fatto Limited Partnership 
Attn:  Broc C. Hiatt and Craig D. Cardon 
1223 S. Clearview Ave., Suite 103 
Mesa, AZ 85209
bhiatt@cardonhiatt.com
	 

	3M Company
	3M Ventures 
3M Company 
3M Center, Building 220-9E-02 
St. Paul, MN 55144-1000 bdwright2@mmm.com
	 

	Iowa Health System D/B/A UnityPoint Health
	UnityPoint Health
1776 West Lakes Parkway, Suite 400 
West Des Moines, IA 50266-8239
matthew.kirschner@unitypoint.org
	 

	Aetna Inc.
	Aetna Inc.
151 Farmington Avenue, RC6A
Hartford, CT 06156
Attention:  General Counsel
Fax:  (860) 273-8430
	Davis Polk & Wardwell LLP
450 Lexington Avenue 
New York, NY 10017 
Attention:  H. Oliver Smith 
And Harold Birnbaum
Fax:  (212) 701-5800

	OrbiMed Royalty Opportunities II, LP
	601 Lexington Avenue, 54th Floor
New York, NY 10022
Attn:  Mark Jelley
jelleym@orbimed.com
cc:  ROSCreditOps@OrbiMed.com
Telephone:  (212) 739-6461
	Covington & Burling LLP
The New York Times Building, 620
Eighth Avenue
New York, NY 10018-1405
Attn:  Peter Schwartz

Schedule of Investors for Series F Investor Rights Agreement

	
			
	Brent C. James
	4 E. Knightsbridge Lane
Salt Lake City, UT 84103-2241
Brent.james@qualityscience.pro
	 

	W David Hemingway
	1213 Canyon Oaks Way 
Salt Lake City, UT 84103 
wdavid.hemingway@gmail.com
	 

Schedule of Investors for Series F Investor Rights AgreementExhibit

Exhibit 4.4

FIFTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT
THIS FIFTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of February 6, 2019, by and among Health Catalyst, Inc., a Delaware corporation (the “Company”), each of the Persons listed on the Schedule of Investors attached hereto (each, an “Investor” and together with any subsequent investors or transferees who become parties hereto as “Investors” pursuant to paragraph 5 below, the “Investors”) and each of the Persons listed on the Schedule of Key Holders attached hereto (each, an “Key Holder” and together with any subsequent investors or transferees who become parties hereto as “Key Holder” pursuant to paragraph 5 below, the “Key Holders”).  The Investors and the Key Holders are collectively referred to herein as the “Stockholders” and individually as a “Stockholder.”  Except as otherwise provided herein, capitalized terms used herein are defined in paragraph 9 hereof.
WHEREAS, certain of the parties to this Agreement are parties to a Stock Purchase Agreement, dated as of February 6, 2019 (the “Stock Purchase Agreement”), pursuant to which, among other things, certain of the Investors shall purchase shares of the Company’s newly authorized Series F Preferred stock, $0.001 par value per share (the “Series F Preferred”).
WHEREAS, certain of the Investors (the “Existing Investors”) hold all of the issued and outstanding shares of the Company’s Series A Preferred stock, $0.001 par value per share (the “Series A Preferred”), Series B Preferred stock, $0.001 par value per share (the “Series B Preferred”), Series C Preferred stock, $0.001 par value per share (the “Series C Preferred”), Series D Preferred stock, $0.001 par value per share (the “Series D Preferred”) and Series E Preferred stock, $0.001 par value per share (the “Series E Preferred”, and together with the Series A Preferred, the Series B Preferred, the Series C Preferred, the Series D Preferred and the Series F Preferred, the “Preferred Stock”), and are parties to that certain Fourth Amended and Restated Stockholders Agreement, dated February 9, 2016, by and among the Company, the Existing Investors, and the Other Stockholders (as defined therein), as amended from time to time (the “Old Stockholders Agreement”), for the purposes, among others, of (i) establishing the composition of the Company’s board of directors (the “Board”), (ii) assuring the continuity of the management and ownership of the Company, (iii) limiting the manner and terms by which the Company’s capital stock may be transferred, and (iv) establishing certain rights in favor of the Existing Investors;
WHEREAS, the Key Holders are each holders of issued and outstanding shares of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”);
WHEREAS, the parties to the Old Stockholders Agreement desire to amend and restate the Old Stockholders Agreement in its entirety to, among other things, add the new Investors as parties; and WHEREAS, the execution and delivery of this Agreement is a condition to the closing (the “Closing”) of the transactions contemplated by the Stock Purchase Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows:

1.Board of Directors.
(a)    From and after the Closing and until the provisions of this paragraph 1 cease to be effective, each holder of Stockholder Shares shall vote all of his, her or its Stockholder Shares which are voting shares and any other voting securities of the Company over which such holder has voting control and shall take all other necessary or desirable actions within his, her or its control (whether in his, her or its capacity as a stockholder, director, member of a board committee or officer of the Company or otherwise, and including attendance at meetings in person or by proxy for purposes of obtaining a quorum and execution of written consents in lieu of meetings), and the Company shall take all necessary or desirable actions within its control (including calling special board and stockholder meetings), so that:
(i)    the authorized number of directors on the Board shall be established and maintained at nine (9) directors;
(ii)    the following persons shall be elected to the Board:
(A)    two (2) representatives designated by Sequoia Capital U.S. Growth Fund IV, L.P. (together with its Affiliates and partners, “Sequoia”), for so long as Sequoia owns beneficially at least 2,500,000 shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of Preferred Stock), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like (the “Sequoia Directors”), who shall initially be Michael Dixon and Anita Pramoda, in each case until otherwise designated by Sequoia;
(B)    two (2) representatives designated by the Key Holders, determined by a vote of the Key Holders owning a majority of the outstanding Key Holder Shares then held by all Key Holders (the “Key Holder Directors”), who shall initially be Fraser Bullock and Tim Ferris, in each case until otherwise designated by the Key Holders;
(C)    one (1) representative designated by Norwest Venture Partners XI, LP (together with its Affiliates and partners, “Norwest”), for so long as Norwest owns beneficially at least 2,500,000 shares of Common Stock of the Company (including shares of Common Stock issued or issuable upon conversion of Preferred Stock), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like (the “Norwest Director”), who shall initially be Promod Haque until otherwise designated by Norwest;
(D)    one (1) representative who is the then current Chief Executive Officer of the Company (the “CEO Director”) who shall initially be Daniel D. Burton; and
(E)    three (3) representatives who are mutually acceptable to the other members of the Board (the “Independent Director”), who shall initially be John A. Kane, Todd Cozzens, and Duncan Gallagher, until otherwise designated by the Board.
(iii)    To the extent that any of clauses (ii)(A) through (ii)(C) above shall not be applicable, any member of the Board who would otherwise have been designated in accordance 

2

with the terms thereof shall instead be voted upon by all the stockholders of the Company entitled to vote thereon in accordance with, and pursuant to, the Company’s Certificate of Incorporation.
(iv)    subject to paragraph 1(a)(v) below, any director of the Company may be removed from the Board in the manner allowed by law and the Company’s or such Subsidiary’s Certificate of Incorporation and Bylaws, each as amended and/or restated from time to time, or similar governing documents; provided that, (A) each Sequoia Director shall be removed without cause only upon the written request of Sequoia, (B) the Norwest Director shall only be removed without cause upon the written request of Norwest, and (C) the Key Holder Directors shall only be removed without cause upon the written request of the Key Holders that hold a majority of the outstanding Stockholder Shares then held by all of the Key Holders; and
(v)    in the event that any representative designated hereunder for any reason ceases to serve as a member of the Board during his or her term of office, the resulting vacancy on the Board shall be filled pursuant to subparagraph (ii) above.
(b)    The Company has previously established an Audit Committee, a Compensation Committee, and a Nominating Committee.  Any other committee of the Board may only be established with the affirmative vote or consent of at least five (5) of the directors.  Upon Sequoia’s request, any committees established by the Board (including the Audit and Compensation Committees) shall include at least one (1) of the Sequoia Directors.
(c)    The Company shall pay the reasonable travel expenses incurred by each director in connection with attending the meetings of the Board and any committee thereof.  The Company shall maintain requisite directors and officers indemnity insurance coverage which is reasonably satisfactory to the Investors, which shall be in effect at all times, and the Company’s Certificate of Incorporation and Bylaws, each as amended and/or restated from time to time, shall at all times provide for indemnification and exculpation of directors to the fullest extent permitted under applicable law.  Unless otherwise agreed in writing by the Investors that hold a majority of the outstanding Stockholder Shares then held by all of the Investors, the Company shall hold a meeting of the Board at least once in each fiscal quarter, and each such meeting shall occur no later than 120 days after the preceding meeting.
(d)    Provisions (a) through (c) of this paragraph 1 shall terminate automatically and shall be of no further force and effect upon the consummation of (i) the IPO, or (ii) a Sale of the Company.
(e)    After the consummation of an IPO and for so long as any Investor (together with its Affiliates) holds an aggregate of at least 5% of the outstanding shares of the Company’s Common Stock, the Company shall nominate a representative designated by such Investor to serve as a member of the Board and take all reasonable actions necessary to effect such Board representation.
(f)    If any Subsidiary of the Company has a board of directors or equivalent governing body, the composition of the board of directors or equivalent governing body of such Subsidiary (each, a “Sub Board”) shall be proportionately equivalent to that of the Board and all provisions of this paragraph 1 shall apply to such Subsidiary and such Sub Boards.

3

2.    Representations and Warranties; Agreements.  Each Stockholder represents and warrants as of the date hereof that (i) this Agreement has been duly authorized, executed and delivered by such Stockholder and constitutes the valid and binding obligation of such Stockholder, enforceable in accordance with its terms, and (ii) such Stockholder has not granted and is not a party to any proxy, voting trust or other agreement which is inconsistent with, conflicts with or violates any provision of this Agreement.  No holder of Stockholder Shares shall grant any proxy or become party to any voting trust or other agreement which is inconsistent with, conflicts with or violates any provision of this Agreement.
3.    Certain Transfer Restrictions.
(a)    Except as required by paragraph 8 hereof, no Key Holder shall sell, transfer, assign, pledge or otherwise dispose of (whether with or without consideration and whether voluntarily or involuntarily or by operation of law or otherwise) any interest in any Stockholder Shares (a “Transfer”), until and in connection with an IPO or a Sale of the Company (“Restricted Period”) without the prior written consent of Investors holding a majority of the outstanding shares of Preferred Stock.  After the expiration of the Restricted Period, no Key Holder shall Transfer any interest in any Stockholder Shares, except pursuant to a Public Sale or a Sale of the Company (an “Exempt Transfer”) or the provisions of this paragraph 3.  For the avoidance of doubt, the Investors shall not be subject to the provisions of this paragraph 3.
(b)    The restrictions contained in this paragraph 3 shall not apply with respect to any Transfer of Stockholder Shares by a Key Holder (i) subject to compliance by the Company with paragraph 1E(i)(b) of the Investor Rights Agreement, (ii) to the Company pursuant to a repurchase of Stockholders Shares from a Key Holder by the Company at a price no greater than that originally paid by such Key Holder for such Stockholder Shares which is consummated pursuant to an agreement containing vesting and/or repurchase provisions approved by a majority of the Board, (iii) pursuant to applicable laws of descent and distribution or (iv) among such Key Holder’s Family Group (collectively referred to herein as “Permitted Transferees”); provided that such restrictions shall continue to be applicable to the Stockholder Shares after any such Transfer and the transferees of such Stockholder Shares shall agree in writing to be bound by the provisions of this Agreement affecting the Stockholder Shares so transferred as a condition precedent to any such Transfer.  For purposes of this Agreement, “Family Group” means the spouse, descendants (whether natural or adopted), siblings, nieces, nephews or any other relative approved by the Board, or any trust established solely for the benefit of such individual and/or such individual’s spouse, descendants, siblings, nieces, nephews, or other relatives approved by the Board.  Notwithstanding the foregoing, no party hereto shall avoid the provisions of this Agreement by making one or more transfers to one or more Permitted Transferees and then disposing of all or any portion of such party’s interest in any such Permitted Transferee.
4.    Holdback Agreement.  No Key Holder shall effect any Transfer, except an Exempt Transfer, of any Stockholder Shares or of any other capital stock or equity securities of the Company, or any securities convertible into or exchangeable or exercisable for such stock or securities, (a) from the date on which the Company gives notice to the holders of registrable securities that a preliminary prospectus has been circulated for an IPO to the date that is 180 days following the date of the final prospectus for such IPO or (b) from the date on which the Company gives notice to the holders of registrable securities of the circulation of a preliminary or final prospectus for any subsequent underwritten registration to the 

4

date that is 90 days following the date of the final prospectus for such subsequent underwritten registration, unless, in each case, the underwriters managing the registration otherwise agree in writing.
5.    Future Sales; Transfers by Stockholders.  Prior to the Company issuing any shares of its capital stock to any Person who is not a party to this Agreement, the Company shall cause such Person to be bound by this Agreement as an Investor or Key Holder, as the case may be, and to execute and deliver to the Company and the Investors and the Key Holders a counterpart of this Agreement.  When a Person becomes party to this Agreement in accordance with the forgoing sentence, the Company shall cause the Schedule of Investors and Schedule of Key Holders attached to this Agreement to be amended to reflect the addition of such Person.  Transferees of shares of Preferred Stock held by Investors shall be deemed to be Investors hereunder.  Transferees of shares of Common Stock of the Company held by Key Holders shall be bound by the provisions of this Agreement as Key Holders.  Notwithstanding the foregoing, the Company may issue shares of its capital stock to employees or consultants or directors of the Company or any of its subsidiaries without such Persons being bound by this Agreement so long as such shares are issued pursuant to the Company’s 2011 Stock Incentive Plan, as amended.
6.    Legend.  Each certificate evidencing Stockholder Shares and each certificate issued in exchange for or upon the Transfer of any Stockholder Shares shall be stamped or otherwise imprinted with a legend in substantially the following form:
“The transfer of the securities represented by this certificate is subject to a Fifth Amended and Restated Stockholders Agreement dated as of February 6, 2019, among the issuer of such securities (the “Company”) and certain of the Company’s stockholders, as the same may be amended or modified from time to time.  A copy of such Fifth Amended and Restated Stockholders Agreement shall be furnished without charge by the Company to the holder hereof upon written request.”
The Company shall imprint such legend on certificates evidencing Stockholder Shares outstanding as of the date hereof.
7.    Preemptive Rights.
(a)    If the Company authorizes the issuance or sale of any shares of Common Stock or any other capital stock of the Company or any securities (including debt securities) containing options or rights to acquire any shares of Common Stock (other than as a dividend on the outstanding shares of capital stock) or any securities exchangeable for or convertible into Common Stock, including any Preferred Stock (collectively, “Securities”), other than in an Exempt Issuance, the Company shall first offer to sell to each of the Eligible Stockholders a portion of such Securities equal to the quotient determined by dividing (A) the number of shares of Common Stock held by such holder (including shares of Common Stock issuable upon conversion of the Preferred Stock) by (B) the Company’s fully-diluted Common Stock then outstanding (including shares of Common Stock issuable upon conversion of the Preferred Stock and the full exercise of outstanding options exercisable for (directly or indirectly) Common Stock).  Each Eligible Stockholder shall be entitled to purchase all or any portion of its allotment of such Securities at the most favorable price and on the most favorable terms as such Securities are issued and sold to any other Persons; 

5

provided that if all Persons entitled to purchase or receive such Securities are required to also purchase other securities of the Company, the Persons exercising their rights pursuant to this paragraph shall also be required to purchase the same strip of securities (on the same terms and conditions) that such other Persons are required to purchase.
(b)    In order to exercise its purchase rights hereunder, an Eligible Stockholder must within 20 days after receipt of written notice from the Company describing in reasonable detail the Securities being offered, the purchase price thereof, the payment terms and such Eligible Stockholder’s percentage allotment, deliver a written notice to the Company describing its election hereunder.  If all of the Securities offered to the Eligible Stockholders are not fully subscribed by such Eligible Stockholders, the remaining Securities shall be reoffered by the Company to the Eligible Stockholders purchasing their full allotment upon the terms set forth in this paragraph, except that such holders must exercise their purchase rights within five (5) days after receipt of such reoffer.
(c)    Upon the expiration of the offering periods described above, the Company shall be entitled to sell such Securities which the Eligible Stockholders have not elected to purchase during the 90 days following such expiration on terms and conditions no more favorable to the purchasers thereof than those offered to such holders.  Any Securities offered or sold by the Company after such 90-day period must be reoffered to the Eligible Stockholders pursuant to the terms of this paragraph.
(d)    In the event that the Company is unable to comply with the provisions of this paragraph 7 at the time of any issuance of Securities due to circumstances related to the issuance of such Securities to a third party, the Company shall give notice to the Eligible Stockholders within 30 days after such issuance of Securities.  Such notice shall describe the type, price, and terms of the Securities.  Each Eligible Stockholder shall have 20 days from the date notice is given to elect to purchase up to the number of Securities that would, if purchased by such Eligible Stockholder, maintain such Eligible Stockholders’ percentage-ownership position, calculated as set forth in paragraph 7(a).  The closing of such sale shall occur within 60 days of the date notice is given to the Eligible Stockholders.
(e)    The provisions of this paragraph 7 shall terminate upon the earlier to occur of (i) immediately before the consummation of an IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act of 1934, as amended, or (iii) a Sale of the Company in which the Investors sell for cash 100% of the shares of capital stock of the Company held by the Investors at the time of such Sale of the Company.
8.    Sale of the Company.
(a)    If (i) the Board, (ii) the holders of a majority of the Series A Preferred voting separately as a class, and (iii) if required pursuant to paragraph 1E(ii)(c) of the Investor Rights Agreement, the holders of at least sixty-six percent (66%) of the outstanding shares of Preferred Stock, determine to effect a Sale of the Company and deliver written notice to the holders of Stockholder Shares invoking the provisions of this paragraph 8 (any such sale, an “Approved Sale”), subject to Section 8(d) below, the holders of Stockholders Shares shall consent to, vote in favor of and raise no objections against the Approved Sale.

6

(b)    Subject to Section 8(d), if the Approved Sale is structured as (i) a merger or consolidation, each holder of Stockholder Shares shall vote such holder’s Stockholder Shares to approve such merger or consolidation, whether by written consent or at a stockholders meeting (as requested by the Investors) and waive all dissenter’s rights, appraisal rights and similar rights in connection with such merger or consolidation, (ii) a sale of stock, each holder of Stockholder Shares shall agree to sell, and shall sell, all of such holder’s Stockholder Shares and rights to acquire Stockholder Shares on the terms and conditions so approved by the Board, the holders of a majority of the Series A Preferred, and, if required pursuant to Section 8(a) above, the holders of at least seventy-five percent (75%) of the outstanding shares of Preferred Stock, or (iii) a sale of assets, each holder of Stockholder Shares shall vote its Stockholder Shares to approve such sale and any subsequent liquidation of the Company or other distribution of the proceeds therefrom, whether by written consent or at a stockholders meeting (as requested by the Board).
(c)    In furtherance of the foregoing, each holder of Stockholder Shares shall take, with respect to such holder’s Stockholder Shares, all necessary or desirable actions reasonably requested by the Board in connection with the consummation of the Approved Sale, including without limitation, voting to approve such transaction and executing the applicable purchase agreement and related documents.
(d)    The obligations of the holders of Stockholder Shares with respect to an Approved Sale are subject to the satisfaction of the following conditions:  (i) upon the consummation of the Approved Sale, each holder of Stockholder Shares will receive the same form of consideration and the same portion of the aggregate consideration that such holders of Stockholder Shares would have received if such aggregate consideration had been distributed by the Company in complete liquidation pursuant to the rights and preferences set forth in the Company’s Certificate of Incorporation as in effect immediately prior to such Approved Sale; (ii) if any holders of a class of Stockholder Shares are given an option as to the form and amount of consideration to be received, each holder of such class of Stockholder Shares will be given the same option; (iii) each holder of then currently exercisable rights to acquire shares of a class of Stockholder Shares will be given an opportunity to exercise such rights prior to the consummation of the Approved Sale and participate in such sale as holders of such class of Stockholder Shares; (iv) the consideration to be received by the Stockholders in connection with such Approved Sale shall, unless otherwise approved by the Board and the holders of a majority of the outstanding Preferred Stock, consist solely of cash and/or public company securities (which are freely tradable within not more than three (3) months following closing, subject only to customary lock-up provisions) from a company with an aggregate “public float” immediately prior to such transaction of not less than $500,000,000; (v) all warranty and indemnification obligations and caps on liability shall be on a pro rata basis based on the consideration received by each Stockholder in connection with the Approved Sale (and none shall be on a joint and several basis), except that necessary individual representations, warranties and covenants particular to individual Stockholders will be made only by such Stockholder (e.g., representations regarding ownership of securities, authority, due execution, knowledge, awareness and breaches of covenants, etc.) and liability with respect thereto will be borne by the breaching party only; (vi) any escrow or holdback of proceeds in connection with such Approved Sale shall be on a pro rata basis among all Stockholders based on the consideration received by (or to be paid to) each Stockholder in connection with such Approved Sale; (vii) no Investor will be required to become bound by any non-competition covenant, restraint, non-solicitation covenant or any similar restrictive covenant without its consent; and (viii) no Stockholder’s liability to the buyer or any other person (including any warranty or indemnification obligations) in connection with such Approved Sale will exceed 

7

the actual amount of proceeds actually received by such Stockholder in consideration for his, her or its Stockholder Shares, other than in the case of fraud or willful misrepresentation.  The condition that each holder of Stockholder Shares receive, or is provided with the same option to receive, the same form of consideration as set forth in clause (i) and clause (ii) above shall be deemed satisfied even if certain holders of Stockholders Shares receive, to the exclusion of others, securities of the entity acquiring the Company in an Approved Sale, so long as each holder of Stockholder Shares receives the same amount of value, whether in cash or such securities, as of the closing of such Approved Sale with respect to such holder’s Stockholder Shares.
(e)    If the Company or the holders of the Company’s securities enter into any negotiation or transaction for which Rule 506 (or any similar rule then in effect) of the Securities Act promulgated by the Securities Exchange Commission may be available with respect to such negotiation or transaction (including a merger, consolidation or other reorganization), the holders of Stockholder Shares shall at the request of the Company, appoint a “purchaser representative” (as such term is defined in Rule 501 of the Securities Act) reasonably acceptable to the Company.  If any holder of Stockholder Shares appoints a purchaser representative designated by the Company, the Company shall pay the fees of such purchaser representative.  However, if any holder of Stockholder Shares declines to appoint the purchaser representative designated by the Company, such holder shall appoint another purchaser representative (reasonably acceptable to the Company), and such holder shall be responsible for the fees of the purchaser representative so appointed.
(f)    Subject to paragraph (e) above, each holder of Stockholder Shares shall, to the extent requested by the Company, pay such holder’s pro rata share of the expenses incurred by the holders in connection with an Approved Sale.
(g)    The provisions of this paragraph 8 shall terminate upon the consummation of an IPO.
9.    Definitions.
“Affiliate” of any particular Person means any other Person controlling, controlled by or under common control with such particular Person, where “control” means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract or otherwise.  Notwithstanding anything to the contrary herein, the Kaiser Entities shall be deemed to be Affiliates of each other.
“Agreement” has the meaning set forth in the preamble hereto.
“Approved Sale” has the meaning set forth in paragraph 8(a).
“Board” has the meaning set forth in the recitals hereto.
“CEO Director” has the meaning set forth in paragraph 1.

8

“Company’s Certificate of Incorporation” means that certain Seventh Amended and Restated Certificate of Incorporation of the Company, dated on or about the date hereof, as amended from time to time.
“Confidential Information” means all information of a confidential or proprietary nature (whether or not specifically labeled or identified as “confidential”), in any form or medium, that relates to the Company or its business relations and activities.  Confidential Information includes, but is not limited to, the following:  (i) internal business information (including historical and projected financial information and budgets and information relating to strategic and staffing plans and practices, business, training, marketing, promotional and sales plans and practices, cost, rate and pricing structures and accounting and business methods); (ii) identities and individual requirements of, and specific contractual arrangements with, the Company’s customers, independent contractors, joint venture partners and other business relations and their confidential information; (iii) trade secrets, know-how, compilations of data and analyses, techniques, systems, formulae, research, records, reports, manuals, documentation, models, data and data bases relating thereto; and (iv) inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether or not patentable).  The term “Confidential Information” shall not apply to anything which, as shown by appropriate written or reliable evidence, is publicly known or generally known in the healthcare or information technology industry or profession or, as shown by appropriate written or reliable evidence, shall become publicly known or generally known in the healthcare or information technology industry or profession, other than by reason of breach by the applicable party bound hereunder or its Affiliates.
“Closing” has the meaning set forth in the recitals hereto.
“Common Stock” has the meaning set forth in the recitals hereto.
“Company” has the meaning set forth in the preamble hereto.
“Covered Persons” means any holder (so long as that holder is a Key Investor, as defined below) of Preferred Stock or any Affiliate, partner, member, director, stockholder, employee, agent or other related person of any such holder, other than someone who is an employee of the Company or any of its Subsidiaries.
“Eligible Stockholder” (i) any Key Holder who holds more than 8% of the Company’s then outstanding capital stock calculated on a fully-diluted basis (including full exercise of outstanding options and/or warrants, but excluding shares reserved for issuance as such), and (ii) each of the Investors and their respective successors and assigns.
Notwithstanding anything to the contrary herein, the aggregate rights of the Kaiser Entities to purchase Securities under Section 7 may be allocated among such entities in their discretion.
“Exempt Issuance” means any issuance of Securities (i) in an IPO, (ii) as consideration in connection with the acquisition of another company or business as to which approval of the holders of a majority of the outstanding Series A Preferred stock under paragraph 1E(i)(g) of the Investor Rights Agreement is either obtained or not required, (iii) to employees or consultants or directors of the Company or any of its subsidiaries pursuant to any plan, agreement, or arrangement approved by the Board and, if 

9

required under paragraph 1E(i)(i) of the Investor Rights Agreement, the holders of a majority of the outstanding Series A Preferred stock, (iv) upon conversion or exercise of, or in exchange for, any securities of the Company or any options or other rights to acquire securities of the Company, (v) pursuant to any stock split, stock dividend, distribution, stock combination, recapitalization or similar transaction that affects all stockholders or holders of any class of securities (as the case may be) proportionately, (vi) to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board, (vii) to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board, or (viii) issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board.
“Exempt Transfer” has the meaning set forth in paragraph 3(a).
“Family Group” has the meaning set forth in paragraph 3(b).
“Independent Director” has the meaning set forth in paragraph 1.
“Investor Directors” means the Sequoia Directors and the Norwest Director.
“Investors” means those Persons identified on the Schedule of Investors attached hereto and such other Persons as may become “Investors” hereunder from time to time under the circumstances described in paragraph 5.
“Investor Rights Agreement” means the Fifth Amended and Restated Investor Rights Agreement, dated on or around the date hereof as amended and/or restated from time to time.
“IPO” means an initial Public Offering.
“Kaiser Entities” shall mean Kaiser Permanente Ventures, LLC—Series A, Kaiser Permanente Ventures, LLC—Series B and The Permanente Federation LLC—Series J.
“Key Holders” means those Persons identified on the Schedule of Key Holders attached hereto and such other Persons as may become “Key Holders” hereunder from time to time under the circumstances described in paragraph 5.
“Key Holder Directors” has the meaning set forth in paragraph 1.
“Key Holder Shares” means Stockholder Shares held by Key Holders.
“OrbiMed” means OrbiMed Royalty Opportunities II, LP.
“Permitted Transferees” has the meaning set forth in paragraph 3(b).
“Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

10

“Preferred Stock” has the meaning set forth in the recitals hereto.
“Public Sale” means any sale of Stockholder Shares to the public pursuant to an offering registered under the Securities Act or to the public through a broker, dealer or market maker pursuant to the provisions of Rule 144 adopted under the Securities Act (or any similar provision then in force).
“Public Offering” means any offering by the Company of its Common Stock to the public pursuant to an effective registration statement under the Securities Act or any comparable statement under any similar federal statute then in force.
“Sale of the Company” means a sale of the Company to a third party or group of third parties pursuant to which such party or parties (i) acquire capital stock or equity interests of the Company possessing the voting power under normal circumstances to elect a majority of the Board (whether by merger, consolidation or sale or transfer of the Company’s capital stock or otherwise) or (ii) acquire or obtain an exclusive license to all or substantially all of the Company’s assets determined on a consolidated basis.
“Securities” has the meaning set forth in paragraph 7.
“Securities Act” means the Securities Act of 1933, as amended from time to time.
“Stock Purchase Agreement” has the meaning set forth in the recitals hereto.
“Stockholder” has the meaning set forth in the preamble hereto.
“Stockholder Shares” means (i) any Common Stock purchased or otherwise acquired or held by any Stockholder, (ii) any Common Stock issued or issuable directly or indirectly upon the conversion, exercise or exchange of any securities purchased or otherwise acquired by any Stockholder which are convertible into or exercisable or exchangeable directly or indirectly for Common Stock (including the Preferred Stock but excluding options to purchase Common Stock granted by the Company unless and until such options are exercised) and (iii) any other capital stock or equity securities issued or issuable directly or indirectly with respect to the securities referred to in clauses (i) or (ii) above by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization.  As to any particular securities constituting Stockholder Shares hereunder, such Stockholder Shares shall cease to be Stockholder Shares hereunder when they have been (x) effectively registered under the Securities Act and disposed of in accordance with the registration statement covering them or (y) sold to the public through a broker, dealer or market maker pursuant to Rule 144 (or any similar provision then in force) under the Securities Act.
“Sub Board” has the meaning set forth in paragraph 1.
“Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a limited liability company, partnership, association or other business entity, a majority of the partnership or 

11

other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof.
“Transfer” has the meaning set forth in paragraph 3(a).
10.    Transfers in Violation of Agreement.  Any Transfer or attempted Transfer of any Stockholder Shares in violation of any provision of this Agreement shall be void, and the Company shall not record such Transfer on its books or treat any purported transferee of such Stockholder Shares as the owner of such Stockholder Shares for any purpose.
11.    Amendments, Waivers and Termination.  Except as otherwise provided herein, no modification, amendment or waiver of any provision of, or termination of, this Agreement shall be effective against the Company or the Stockholders unless such modification, amendment, waiver or termination is approved in writing by the Company, the Investors that held a majority of the Stockholder Shares then held by the Investors and the Key Holders that held a majority of the Stockholder Shares then held by the Key Holders.  Each Stockholder agrees that any modification, amendment, waiver or termination so approved shall be binding on such Stockholder, whether or not such Stockholder executed such modification, amendment, waiver or termination, provided that such modification, amendment, waiver or termination applies to all Stockholders of a class of the Company’s securities in the same fashion (it being agreed that a waiver of the provisions of Section 7 with respect to a particular transaction shall be deemed to apply to all Stockholders in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Stockholders may nonetheless, by agreement with the Company, purchase securities in such transaction, subject to clause (d) below).  Notwithstanding the foregoing, (a) neither Section 1(a)(ii)(A) nor Section 1(a)(iii) shall be amended, modified or waived without the prior written consent of Sequoia, (b) neither Section 1(a)(ii)(C) nor Section 1(a)(iii) shall be amended, modified or waived without the prior written consent of Norwest, (c) neither item (iii) of Section 8(a) or item (ii) of Section 8(b) shall be amended, modified or waived without the prior written consent of the holders of at least sixty-six percent (66%) of the Preferred Stock, (d) if, after giving effect to any waiver of Section 7 or any provision pertaining to Section 7 with respect to a particular transaction, any of Sequoia, Norwest, or OrbiMed (each a “Participating Investor”) purchases Securities in such transaction, such waiver of the provisions of Section 7 shall be deemed to apply to each other Participating Investor only if each such Participating Investor has been provided the opportunity to purchase a proportional number of the Securities offered in such transaction based on the pro rata purchase right of each such Participating Investor set forth in Section 7 assuming a transaction size determined based upon the amount purchased by the Participating Investor that invested the largest percentage in such transaction, (e) if an amendment would treat an Investor in a materially disproportionate and adverse manner relative to the other Investors, then the amendment shall also require the consent of such Investor so adversely treated, and (f) (i) the consent of the Key Holders shall not be required for any modification, amendment or waiver if such modification, amendment or waiver does not (A) apply to the Key Holders, or (B) adversely affect any of the rights of the Key Holders hereunder, and (ii) the Schedule of Investors and Schedule of Key Holders hereto may be amended by the Company from time to time in accordance with paragraph 5 without the consent of the other parties hereto.  The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms.

12

12.    Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement in such jurisdiction or affect the validity, legality or enforceability of any provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
13.    Amendment of Old Stockholders Agreement; Entire Agreement.  The Old Stockholders Agreement is hereby amended and restated in its entirety by this Agreement and the provisions of the Old Stockholders Agreement shall no longer be of any force or effect.  This Agreement (including the schedules hereto) and the Transaction Agreements (as that term is defined in the Stock Purchase Agreement) contain the complete agreement between the parties hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations by or between the parties hereto (whether written or oral) which may have related to the subject matter hereof or thereof in any way (including, without limitation, the Old Stockholders Agreement).
14.    Successors and Assigns.  Except as otherwise expressly provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Company and its successors and assigns and the Stockholders and any subsequent holders of Stockholder Shares and the respective successors and assigns of each of them, so long as they hold Stockholder Shares.
15.    Counterparts.  This Agreement may be executed in multiple counterparts (including by means of facsimile signature pages), each of which shall be an original and all of which taken together shall constitute one and the same agreement.
16.    Remedies.  The parties hereto shall be entitled to enforce their rights under this Agreement specifically, to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights existing in their favor.  The parties hereto agree and acknowledge that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that the Company and any Stockholder may in its sole discretion apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of the provisions of this Agreement.
17.    Notices.  All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (i) when delivered personally to the recipient, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; provided that such notice under this clause (ii) shall not be effective unless within one business day of the notice a copy of such notice is dispatched to the recipient by first class mail, return receipt requested, or reputable overnight courier service (charges prepaid), (iii) one business day after it is sent to the recipient by reputable overnight courier service (charges prepaid) or (iv) five days after it is mailed to the recipient by first class mail, return receipt requested.  Such notices, demands and other communications shall be sent to the Company at the address specified below, to the Investors at the addresses indicated on the Schedule of Investors attached 

13

hereto, to the Key Holders at the addresses indicated on the Schedule of Key Holders attached hereto, and to any subsequent Stockholder subject to this Agreement at such address as indicated by the Company’s records, or at such address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party.  Any party may change its address for receipt of notice by providing sending prior written notice of the change to the sending party.
The Company’s address is:
The Company:
Health Catalyst, Inc. 
3165 East Millrock Drive, Suite 400 
Salt Lake City, UT 84121 
Attention:    Dan Orenstein 
Telephone:    (801) 708-6800 
Telecopy:    (801) 365-0076
18.    Governing Law.  The corporate law of the State of Delaware shall govern all issues hereunder concerning the relative rights of the Company and its Stockholders.  All other issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement and the schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.
19.    Certain Waivers.  Each of the Existing Investors and Key Holders hereby waives any existing preemptive rights with respect to the issuance and sale of the Series F Preferred stock to the Investors under the Stock Purchase Agreement (and the issuance of any Common Stock upon conversion thereof).
20.    Business Days.  If any time period for giving notice or taking action hereunder expires on a day which is a Saturday, Sunday or legal holiday in the state in which the Company’s chief executive office is then located, the time period shall automatically be extended to the business day immediately following such Saturday, Sunday or legal holiday.
21.    Descriptive Headings, etc.  The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.  The use of the term “including” herein shall mean “including without limitation.” Any reference to the masculine, feminine or neuter gender shall be deemed to include any gender or all three as appropriate.
22.    Third Party Beneficiaries.  The parties hereto acknowledge and agree that all rights and privileges (including approvals and consents and rights to provide or withhold approval or consent) that may be exercised hereunder by a Key Investor (as defined below) may be exercised by such Key Investor on behalf of itself and on behalf of any Affiliate of such Key Investor, and each Key Investor may apportion any such rights to its Affiliates as the Key Investor deems appropriate.  “Key Investors” shall mean each of Sequoia Capital, Norwest Venture Partners, Leerink Capital, OrbiMed, Sorenson Capital, 

14

Sands Capital, and UPMC, and to the extent applicable, the family of investment funds, general partner entities, and related entities that are Affiliates of such Key Investor.  Notwithstanding anything to the contrary in this Agreement, this paragraph 22 may not be amended or modified without the prior written consent of the Key Investors.
23.    Investment Opportunities and Conflict of Interest.  The Company and the Stockholders acknowledge that Key Investors and their respective Affiliates, members, equity holders, director representatives, partners, employees, agents and other related persons are engaged in the business of investing in private and public companies in a wide range of industries, including the industry segment in which the Company operates (the “Company Industry Segment”).  Accordingly, the Company and the Stockholders acknowledge and agree that a Covered Person shall:
(a)    have no duty to the Company or to any Stockholder to refrain from participating as a director, investor or otherwise with respect to any company or other person or entity, including any such company or other person or entity that is engaged in the Company Industry Segment or is otherwise competitive with the Company, and
(b)    in connection with making investment decisions, to the fullest extent permitted by law, have no obligation of confidentiality or other duty to the Company or to any Stockholder to refrain from using any information, including, but not limited to, market trend and market data, which comes into such Covered Person’s possession, whether as a director, investor or otherwise (the “Information Waiver”), provided that the Information Waiver shall not apply, and therefore such Covered Person shall be subject to such obligations and duties as would otherwise apply to such Covered Person under applicable law, if the information at issue (i) constitutes material non-public information concerning the Company, or (ii) is covered by a contractual obligation of confidentiality to which the Company is subject.
Notwithstanding anything in this paragraph 23 to the contrary, nothing herein shall be construed as a waiver of any Covered Person’s duty of loyalty or obligation of confidentiality with respect to the disclosure of confidential information of the Company, including the obligations set forth in paragraph 24 below.
24.    Confidentiality.  Each of the Stockholders agrees not to disclose at any time (and shall cause each of their respective Affiliates not disclose or use at any time) any Confidential Information (whether or not such information is or was developed by the Stockholder), except to the extent that such disclosure is (a) related to and required by the performance of such Stockholder’s duties to the Company or otherwise in the best interest of the Company, (b) related to the Investors’ investments in the Company and made by the Investors or their respective Affiliates to any current or prospective limited partner of a Key Investor, or (c) made by the Investors or their respective Affiliates to any prospective purchaser of the Investors’ interests in the Company if such prospective purchaser has entered into a customary nondisclosure agreement with respect to such disclosed Confidential Information.  Each of the Key Holders further agrees to take all appropriate steps (and to cause their respective Affiliates to take all appropriate steps) to safeguard such Confidential Information and to protect it against unauthorized disclosure, misuse, espionage, loss and theft.  Each of the Investors further agrees to safeguard such Confidential Information and to protect it against unauthorized disclosure, misuse, espionage, loss and theft, in each case, with the same of level of care and to the same extent that the Key Investors safeguard and protect such information of their other 

15

portfolio companies.  In the event that any of the Stockholders is required by law, court order or the order or request of a government agency or entity to disclose any Confidential Information, such Stockholder shall promptly notify the Company in writing (unless prohibited or requested not to do so by law, court order or the order or request of a government agency or entity), which notification shall include the nature of the legal requirement and the extent of the required disclosure, and shall cooperate with the Company, at its expense, to preserve the confidentiality of such information consistent with applicable law.  If and to the extent that a Stockholders lawfully receives from a third party an item of information that is the same as an item of Confidential Information, then the following will apply:  (a) if the item of information is received on a non-confidential basis then nothing above in this paragraph 24 will apply to such item; and (b) if the item of information is received on a confidential basis then the above provisions in this paragraph 24 will not prevent the Stockholder from disclosing or using such item of information to the extent lawfully permitted by the third party.  Nothing in (a) or (b) allows the Stockholder to infringe any copyright, patent, or other intellectual property rights of the Company.
25.    No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question or intent or interpretation arises, this Agreement shall be construed as it was drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of any of the provisions of this Agreement.  The parties hereto intend that each covenant contained herein shall have independent significance.  If any party has breached any covenant contained herein in any respect, the fact that there exists another covenant relating to the same or similar subject matter (regardless of the relative levels of specialty) which the party has not breached shall not detract from or mitigate the fact that the party is in breach of the first covenant.
* * * * *

16

IN WITNESS WHEREOF, the parties hereto have executed this Investor Rights Agreement on the date first written above.
	
		
	COMPANY:

	 
	 

	HEALTH CATALYST, INC

	 
	 

	By:
	/s/ Daniel D. Burton

	Name:
	Daniel D. Burton

	Title:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS:

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND IV, L.P.

	SEQUOIA CAPITAL USGF PRINCIPALS FUND IV, L.P.

	 
	 

	By:
	SCGF IV Management, L.P., a Cayman Islands exempted limited partnership, General Partner of Each

	 
	 

	By:
	SC US (TTGP), LTD., a Cayman Islands limited liability company

	 
	 

	Its:
	General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Managing Director

	 
	 

	SC US GF V HOLDINGS, LTD.

	a Cayman Islands exempted company

	 
	 

	By:  Sequoia Capital U.S. Growth Fund V, L.P. and Sequoia Capital USGF Principals Fund V, L.P., both Cayman Islands Exempted Limited Partnerships, its Members

	 
	 

	By:  SCGF V Management, L.P.,

	a Cayman Islands Exempted Limited Partnership, its General Partner

	 
	 

	By:  SC US (TTGP), LTD.,

	a Cayman Islands Exempted company, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND V, L.P.

	a Cayman Islands exempted limited partnership

	 
	 

	By:
	SCGF V MANAGEMENT, L.P.,

	a Cayman Islands exempted limited partnership, its General Partner

	 
	 

	By:
	SC US (TTGP), LTD.,

	a Cayman Islands exempted company, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	NORWEST VENTURE PARTNERS XI, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

	 
	 

	NORWEST VENTURE PARTNERS XII, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	HQC ACQUISITION, LLC

	 
	 

	By:
	/s/ Fraser Bullock

	Name:
	Fraser Bullock

	Title:
	President

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES A

	 
	 

	By:
	/s/ Thomas Meier

	Name:
	Thomas Meier

	Title:
	SVP & Treasurer

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES B

	 
	 

	By:
	/s/ Chris Grant

	Name:
	Chris Grant

	Title:
	Member, Managing Committee

	 
	 

	THE PERMANENTE FEDERATION LLC - SERIES J

	 
	 

	By:
	/s/ Anne Cadwell

	Name:
	Anne Cadwell

	Title:
	CFO

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	CHV FUND II, LLC

	 
	 

	By:
	CHV Fund II Management, LLC

	Its:
	Manager

	 
	 

	By:
	/s/ John D. Huesing

	Name:
	John D. Huesing

	Its:
	Authorized Representative

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P.

	Its:
	General Partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC2, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC3, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC4, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P., its general partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC, its general partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	TENAYA CAPITAL VI, LP

	 
	 

	By:
	Tenaya Capital VI GP, LLC, its General Partner

	 
	 

	By:
	/s/ Dorian Merritt

	Name:
	Dorian Merritt

	Its:
	Attorney-In-Fact

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ZIONS SBIC LLC

	 
	 

	By:
	/s/ Kent Madsen

	Name:
	Kent Madsen

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	BRIGHAM YOUNG UNIVERSITY,

	a Utah nonprofit corporation

	 
	 

	(in connection with its Cougar Capital program)

	 
	 

	By:
	/s/ G P Williams

	Name:
	G P Williams

	Title:
	Faculty Advisor

Cougar Capital contact information:
Brigham Young University, 
a Utah nonprofit corporation 
c/o Cougar Capital Program 
David Paul – Treasurer 
A-153 ASB 
Provo. UT 84602 
Email:  davidwpaul@byu.edu 
Phone:  801-422-4887

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UNIVERSITY GROWTH FUND I, L.P.

	 
	 

	By:
	UGFIGP,LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Tom Stringham

	Name:
	Tom Stringham

	Its:
	Manager

	 
	 

	By:
	/s/ Peter Harris

	Name:
	Peter Harris

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UPMC

	 
	 

	By:
	/s/ C. Talbot Heppenstall, Jr.

	Name:
	C. Talbot Heppenstall, Jr.

	Its:
	Treasurer

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	OSF HEALTHCARE SYSTEM,

	an Illinois not for profit corporation

	 
	 

	By:
	/s/ Robert C. Sehring

	Name:
	Robert C. Sehring

	Its:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ John A. Kane

	John A. Kane

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	JOHN MUIR HEALTH

	 
	 

	By:
	/s/ Chris Pass

	Name:
	Chris Pass

	Its:
	Chief Financial Officer

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	IOWA HEALTH SYSTEM D/B/A UNITYPOINT HEALTH

	 
	 

	By:
	/s/ Matthew Kirschner

	Name:
	Matthew Kirschner

	Title:
	Vice President, Treasury

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ORBIMED ROYALTY OPPORTUNITIES II, LP

	 
	 

	By OrbiMed Advisors LLC,

	its investment manager

	 
	 

	By:
	/s/ W. Carter Neild

	Name:
	W. Carter Neild

	Its:
	Member

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ Brent C. James

	Brent C. James

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ W. David Hemingway

	W. David Hemingway

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
	
	KEYHOLDERS:

	 

	/s/ Steven C. Barlow

	Steven C. Barlow

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	KEYHOLDERS:

	 
	 

	THOMAS DAVID BURTON AND PATRICIA CARDON

	BURTON MULTI-GENERATIONAL TRUST II

	 
	 

	By:
	/s/ Thomas D. Burton

	Name:
	Thomas D. Burton

	Its:
	Trustee

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
		
	KEYHOLDERS:

	 
	 

	BURTON 2013 DESCENDANTS TRUST

	 
	 

	By:
	/s/ Patricia Cardon Burton

	Name:
	Patricia Cardon Burton

	Its:
	Trustee

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

	
			
	 	KEYHOLDERS:

	 
	 	CATALYST INVESTMENTS, LLC

	 	 
	 

	 	By:
	/s/ Patricia Cardon Burton

	 	Name:
	Patricia Cardon Burton, acting under Authority of the

	 	General Partner of Burton Family Pavilions, L.P.

[Signature Page to Fifth Amended and Restated Stockholders Agreement]

SCHEDULE I
SCHEDULE OF INVESTORS
	
			
	Investor:
	Notice Address:
	With a copy to (which shall not constitute notice to such Investor):

	Sequoia Capital 
U.S. Growth 
Fund V, L.P.
	c/o Sequoia Capital 
2800 Sand Hill Road, Suite 101 
Menlo Park, CA 94025 
Telephone:  (650) 854-3927 
Telecopy:  (650) 854-2977 
Attention:  Michael Dixon
	Kirkland & Ellis LLP 
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	SC US GF V Holdings, LTD.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital USGF Principals Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital U.S. Growth
Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture Partners XI, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture
Partners XII, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

Schedule of Key Holders for Fifth Amended and Restated Stockholders Agreement

	
			
	HQC Acquisition,
LLC
	c/o Sorenson Capital 
3400 Ashton Blvd., Suite 400 
Lehi, UT 84043 
Telephone:  (801) 407-8444 
Telecopy:  (801) 407-8410 
Attention:  Fraser Bullock
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Matoaka, LLC
	c/o Sequoia Capital 
2800 Sand Hill Road, Suite 101 
Menlo Park, CA 94025 
Telephone:  (650) 854-3927 
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP 
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050 
Telecopy:  (650) 859-7500 
Attention:  Adam D. Phillips

	Todd Cozzens
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025 Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP
3330 Hillview Avenue Palo Alto, CA 94304 Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Kaiser Permanente Ventures, LLC -Series A
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	Kaiser Permanente Ventures, LLC -Series B
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	The Permanente Federation LLC -Series J
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	CHV Fund II, LLC
	340 W. 10th Street, Suite 2100 Indianapolis, IN 46202 Attention:  John D. Huesing Telephone:  (317) 963-1310
	 

	Partners HealthCare System, Inc.
	101 Huntington Avenue, 4th Floor
Boston, MA 02199
Attn:  Roger Kitterman
Telephone:  (617) 954-9500
Fax:  (917) 954-9356
	 

	Sands Capital Private Growth
Fund, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth
Fund-HC, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

Schedule of Investors for Fifth Amended and Restated Stockholders Agreement

	
			
	Sands Capital Private Growth
Fund-HC2, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth
Fund-HC3, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC4, L.P
	Jonathan P. Goodman, General Counsel 1000 Wilson Blvd., Suite 3000 Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Allina Health System
	2925 Chicago Avenue 
Minneapolis, MN 55407 
Telephone:  (612) 262-5403 
Facsimile:  (612) 262-4264 
Attention:  General Counsel
	Faegre Baker Daniels LLP 
2200 Wells Fargo Center 
90 South Seventh Street 
Minneapolis, MN 55402-3901 
Telephone:  (612) 766-7790 
Telecopy:  (612) 554-6467
Attention:  Mark D. Pihlstrom

	Tenaya Capital
VI, LP
	c/o Tenaya Capital, LLC
3280 Alpine Road
Portola Valley, CA 94028
Phone:  650-687-6500
Attn:  Stewart Gollmer and Dave Markland
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Zions SBIC LLC
	15 West South Temple #500 
Salt Lake City, UT 84111 
Attn:  Kent Madsen
	Kirkland & Ellis LLP
3330 Hillview Avenue 
Palo Alto, CA 94304 
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Leavitt Equity Partners I, L.P.
	299 S. Main Street, Suite 2300 
Salt Lake City, UT 84111 
Attn:  Taylor Leavitt
	 

	Brigham Young University (Cougar Capital)
	Brigham Young University, 
a Utah nonprofit corporation 
c/o Cougar Capital Program 
David Paul – Treasurer 
A-153 ASB
Provo, UT 84602
Email:  davidwpaul@byu.edu 
Phone:  801-422-4887
	 

Schedule of Investors for Fifth Amended and Restated Stockholders Agreement

	
			
	University Growth Fund I, L.P.
	University Growth Fund 
299 South Main, Suite 357 
Salt Lake City, UT 84111 
Attn:  Tom Stringham
	 

	UPMC
	UPMC
U.S. Steel Tower, Suite 6071
600 Grant Street
Pittsburgh, PA 15219
Attn:  Senior Associate Counsel and
Vice President
	 

	OSF Healthcare System
	Attn:  Robert C. Sehring, CEO 
800 NE Glen Oak Avenue 
Peoria, IL 61603. 
Fax:  309-655-6869
	 

	Leerink Capital Investors I L.P.
	One Federal Street 
Boston, MA 02110 
 Attn:  Todd Cozzens
	 

	Leerink Transformation Fund I L.P.
	One Federal Street, 25th Floor
Boston, MA 02110
Attn:  Todd Cozzens 
Phone:  (617) 918-4821
Fax:  (617) 918-4921
todd@LTPequity.com
	 

	MultiCare Health System
	MultiCare Health System 
737 S. Fawcett Ave. 
MS:  737-4-CFO 
Tacoma, WA 98402 
Attn:  Judy Swain 
Phone:  253.459.8003 
Fax:  253.459.7854
Judy.swain@multicare.org
	 

	John A. Kane
	18242 Via Caprini Drive 
Ft Myers, FL 33913 
Fax:  239-689-8187
Cell:  802-999-6769
Email jackakane@gmail.com
	 

	John Muir Health
	1450 Treat Blvd Suite #350 
Walnut Creek, CA 94597 
Attn:  Ravi Hundal M.D. or 
Taejoon Ahn M.D. MPH CPE 
Taejoon.Ahn_MD@johnmuirhealth.com
	1400 Treat Boulevard 
Walnut Creek, CA 94597 
Attn:  General Counsel 
Phone:  925-941-2217
Fax:  925-952-2979
max.reynolds@johnmuirhealth.com

Schedule of Investors for Fifth Amended and Restated Stockholders Agreement

	
			
	John Muir Medical Group, Inc.
	1400 Treat Boulevard 
Walnut Creek, CA 94597 
Attn:  Chris Pass, CFO 
Phone:  (925) 941-2622
Fax:  (925) 952-2979
chris.pass@johnmuirhealth.com
	 

	Omkara LLC
	Omkara LLC 
c/o Anita Pramoda 
6085 West Twain Ave., Suite 101 
Las Vegas, NV 89103
	 

	Ben Fatto Limited Partnership
	Ben Fatto Limited Partnership 
Attn:  Broc C. Hiatt and Craig D. Cardon 
1223 S. Clearview Ave., Suite 103 
Mesa, AZ 85209
bhiatt@cardonhiatt.com
	 

	3M Company
	3M Ventures 
3M Company 
3M Center, Building 220-9E-02 
St. Paul, MN 55144-1000 bdwright2@mmm.com
	 

	Iowa Health System D/B/A UnityPoint Health
	UnityPoint Health
1776 West Lakes Parkway, Suite 400 
West Des Moines, IA 50266-8239
matthew.kirschner@unitypoint.org
	 

	Aetna Inc.
	Aetna Inc.
151 Farmington Avenue, RC6A
Hartford, CT 06156
Attention:  General Counsel
Fax:  (860) 273-8430
	Davis Polk & Wardwell LLP
450 Lexington Avenue 
New York, NY 10017 
Attention:  H. Oliver Smith 
And Harold Birnbaum
Fax:  (212) 701-5800

	OrbiMed Royalty Opportunities II, LP
	601 Lexington Avenue, 54th Floor
New York, NY 10022
Attn:  Mark Jelley
jelleym@orbimed.com
cc:  ROSCreditOps@OrbiMed.com
Telephone:  (212) 739-6461
	Covington & Burling LLP
The New York Times Building, 620
Eighth Avenue
New York, NY 10018-1405
Attn:  Peter Schwartz

	Brent C. James
	4 E. Knightsbridge Lane
Salt Lake City, UT 84103-2241
Brent.james@qualityscience.pro
	 

	W David Hemingway
	1213 Canyon Oaks Way 
Salt Lake City, UT 84103 
wdavid.hemingway@gmail.com
	 

Schedule of Investors for Fifth Amended and Restated Stockholders Agreement

SCHEDULE OF KEY HOLDERS
Thomas D. Burton 
2827 Wayman View Court 
Salt Lake City, UT 84117
Steven C. Barlow 
1896 Browns Park Drive 
Bountiful, UT 84010
David Burton 
1040 Oak Hills Way 
Salt Lake City, UT 84108
HB Ventures Consulting, LLC dba HB Strategy Group 
5019 Old Oak Lane 
Highland, UT 84003
Dale Sanders 
2960 E. Juliet Way 
Cottonwood Heights, UT 84121
Thomas David Burton, Trustee of the Thomas David Burton and Patricia Cardon Burton Multi-Generational Trust II 
2827 Wayman View Court 
Salt Lake City, UT 84117
Patricia Cardon Burton, Trustee of the Burton 2013 Descendants Trust 
2827 Wayman View Court 
Salt Lake City, UT 84117
Catalyst Investments, LLC 
2827 Wayman View Court 
Salt Lake City, UT 84117
Health Care DataWorks, Inc. 
c/o MemorialCare Innovation Fund 
320 Golden Shore Ave., Suite 120 
Long Beach, CA 90802 
Attention:  Brant Heise 
Fax No:  562-432-0091
Cedars-Sinai Medical Center 
8700 Beverly Blvd. 
Los Angeles, CA 90048

Schedule of Key Holders for Fifth Amended and Restated Stockholders Agreement

Next Wave Health, LLC 
63B Sunset Lake Road 
Huntsville, TX, 77340
MemorialCare Innovation Fund, L.P. 
320 Golden Shore Ave., Suite 120 
Long Beach, CA 90802
Brent James 
4 E. Knightsbridge Lane 
Salt Lake City, UT 84103
Stanford Health Care 
300 Pasteur Dr. 
Stanford, CA 94304

Schedule of Investors for Fifth Amended and Restated Stockholders Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]